AEON
Price
$0.17Alerts
Change
-$0.01 (-5.56%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
8.77M
2 days until earnings call
Intraday BUY SELL Signals
GERN
Price
$1.02Alerts
Change
+$0.05 (+5.15%)
Updated
Nov 11 closing price
Capitalization
635.92M
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AEON vs GERN

AEON vs GERN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AEON vs. GERN commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AEON is a Hold and GERN is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AEON with price predictions
Nov 10, 2026

AEON's RSI Oscillator ascends from oversold territory

The RSI Oscillator for AEON moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 29 of the 35 cases the stock moved higher. This puts the odds of a move higher at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +14.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where AEON advanced for three days, in 161 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

AEON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AEON as a result. In 60 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.

The Moving Average Convergence Divergence Histogram (MACD) for AEON turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 26 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.

AEON moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AEON crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for AEON entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.571) is normal, around the industry mean (3.498). P/E Ratio (-0.039) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. AEON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for GERN with price predictions
Nov 10, 2026

GERN sees its Stochastic Oscillator recovers from oversold territory

On November 04, 2026, the Stochastic Oscillator for GERN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 58 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GERN's RSI Indicator exited the oversold zone, 24 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for GERN just turned positive on November 10, 2026. Looking at past instances where GERN's MACD turned positive, the stock continued to rise in 41 of 55 cases over the following month. The odds of a continued upward trend are 75%.

Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where GERN advanced for three days, in 165 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

GERN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GERN as a result. In 90 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GERN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

The Aroon Indicator for GERN entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. GERN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.909) is normal, around the industry mean (3.498). P/E Ratio (-8.998) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (16.670) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.250) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GERN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
GERN: Fundamental Ratings
GERN
OUTLOOK RATING
1..100
5
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
79
P/E GROWTH RATING
1..100
14
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AEONGERN
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 13 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (AEON: $0.18 vs. GERN: $0.97)
Brand notoriety: AEON and GERN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AEON: 3% vs. GERN: 121%
Market capitalization -- AEON: $8.77M vs. GERN: $635.92M
AEON [@Biotechnology] is valued at $8.77M. GERN’s [@Biotechnology] market capitalization is $635.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AEON’s FA Score shows that 0 FA rating(s) are green while GERN’s FA Score has 1 green FA rating(s).

  • AEON’s FA Score: 0 green, 5 red.
  • GERN’s FA Score: 1 green, 4 red.
According to our system of comparison, GERN is a better buy in the long-term than AEON.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AEON’s TA Score shows that 4 TA indicator(s) are bullish while GERN’s TA Score has 5 bullish TA indicator(s).

  • AEON’s TA Score: 4 bullish, 6 bearish.
  • GERN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, GERN is a better buy in the short-term than AEON.

Price Growth

AEON (@Biotechnology) experienced а -15.50% price change this week, while GERN (@Biotechnology) price change was +4.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

AEON is expected to report earnings on Nov 13, 2026.

GERN is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

AEON and

Correlation & Price change

A.I.dvisor tells us that AEON and GERN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AEON and GERN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AEON
1D Price
Change %
AEON100%
-1.38%
GERN - AEON
32%
Poorly correlated
-2.24%
PTGX - AEON
28%
Poorly correlated
+0.26%
BLRX - AEON
28%
Poorly correlated
-13.53%
VIVS - AEON
27%
Poorly correlated
-10.76%
IONS - AEON
25%
Poorly correlated
-9.06%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PW7.050.19
+2.77%
Power REIT
OM4.220.10
+2.43%
Outset Medical Inc
DXC15.310.13
+0.86%
DXC Technology Company
SRTA6.02-0.03
-0.50%
Strata Critical Medical Inc
WSO311.47-4.95
-1.56%
Watsco